Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BRLI: 31.82 (+0.55), AXGN: 3.85 (+0.17), AZPN: 36.69 (+0.28), ARQL: 1.15 (+0.01), ADUS: 23.80 (-0.19)
AxoGen, Inc. Avance(R) Nerve Graft Recipient to be honored on Donate Life Rose Parade Float on New Year's Day
GlobeNewswire - Tue Dec 23, 6:02AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a high-growth medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, announced that Shirley Pincus, one of the thousands of patients who have had injured nerves repaired with AxoGen's Avance(R) Nerve Graft, will be honored as a recipient of donated nerve tissue as a float rider in the 2015 Rose Parade aboard the Donate Life Rose Parade Float in Pasadena, California on New Year's Day.
AXGN: 3.85 (+0.17)
AxoGen, Inc. (AXGN) Jumps 5.45% on Insider Buying - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 8:18AM CST
AxoGen, Inc. (AXGN) was a big mover last session, as the company saw its shares rise by over 5% on the day.
AXGN: 3.85 (+0.17), AKRX: 36.47 (+0.43)
PDS Biotechnology, Inc. Announces Appointment of Biotech Industry Leader Sir Richard Sykes to its Board of Directors as Executive Chairman
PR Newswire Europe - Thu Dec 18, 9:41AM CST
PDS Biotechnology, a clinical stage immunotherapeutics company developing the powerful Versamune(R) nanoparticle technology, is delighted to announce that Sir Richard Sykes has accepted an invitation to join the company's board of directors as Executive Chairman.
AXGN: 3.85 (+0.17)
AxoGen perks up
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 8:22AM CST
AXGN: 3.85 (+0.17)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
BGFV: 14.46 (-0.12), AXGN: 3.85 (+0.17), BRK.B: 151.54 (-0.21), Y: 466.26 (-0.32), BIOD: 1.36 (-0.04)
Will AxoGen (AXGN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:05AM CST
Will AxoGen (AXGN) Continue to Surge Higher?
AXGN: 3.85 (+0.17)
AxoGen, Inc. CEO Karen Zaderej to Be Interviewed on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" on December 2
GlobeNewswire - Tue Dec 02, 6:17AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a high-growth medical technology company focused on the peripheral nerve repair market, announced today that Chief Executive Officer (CEO) Karen Zaderej will be interviewed live by host Michael Yorba on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" Show. In this exclusive interview, Ms. Zaderej will discuss AxoGen's unique and innovative portfolio of peripheral nerve repair solutions that offer alternatives to the more than 900,000 patients each year who require surgical repair of an injured peripheral nerve. She will also discuss the Company's strong year-on-year growth and its strategy for becoming the market leader of the $1.6 billion peripheral nerve repair market in the US.
AXGN: 3.85 (+0.17)
AxoGen, Inc. CEO Karen Zaderej to Be Interviewed on Clear Channel -- iHeart Business Talk Radio's "The Trader's Network" on December 2nd, 2014
Marketwired - Tue Dec 02, 6:15AM CST
AxoGen, Inc. (NASDAQ: AXGN), a high-growth medical technology company focused on the peripheral nerve repair market, announced today that Chief Executive Officer (CEO) Karen Zaderej will be interviewed live by host Michael Yorba on Clear Channel -- iHeart Business Talk Radio's "The Trader's Network" Show. In this exclusive interview, Ms. Zaderej will discuss AxoGen's unique and innovative portfolio of peripheral nerve repair solutions that offer alternatives to the more than 900,000 patients each year who require surgical repair of an injured peripheral nerve. She will also discuss the Company's strong year-on-year growth and its strategy for becoming the market leader of the $1.6 billion peripheral nerve repair market in the US. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel's nationally syndicated iHeart Radio stream.
AXGN: 3.85 (+0.17)
AxoGen (AXGN) Looks Good: Stock Adds 5.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:46AM CST
AxoGen (AXGN) was a big mover last session, with shares rising nearly 6% on the day.
IPXL: 31.32 (+0.26), AXGN: 3.85 (+0.17), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)
PDL BioPharma Announces Successful Conclusion of Revenue Interest Agreement with AxoGen
PR Newswire - Fri Nov 14, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company has received $30.3 million, in addition to previously received revenue interest payments, to conclude PDL's revenue interest agreement with AxoGen, Inc. (NASDAQ: AXGN). In October 2012, PDL entered into a structured financing transaction in which PDL provided AxoGen with an aggregate of $20.8 million in exchange for royalties on certain AxoGen revenues. AxoGen is a regenerative medicine company dedicated to advancing the science and commercialization of surgical solutions for peripheral nerve repair.
AXGN: 3.85 (+0.17), PDLI: 7.61 (unch)
AxoGen's (AXGN) CEO Karen Zaderej on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 7:19PM CST
AXGN: 3.85 (+0.17)
AxoGen beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 5:41PM CST
AXGN: 3.85 (+0.17)
AxoGen, Inc. Signs Agreement with Oberland Capital
GlobeNewswire - Thu Nov 13, 3:09PM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, has entered into a $28.55 million financing agreement with Three Peaks Capital S.a.r.l., an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP (collectively "Oberland"
AXGN: 3.85 (+0.17), PDLI: 7.61 (unch)
AxoGen, Inc. Reports 58% Third Quarter Revenue Growth
GlobeNewswire - Thu Nov 13, 3:09PM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, grew revenue during the third quarter to $4.67 million, up 58% as compared to the year ago third quarter revenue of $2.96 million. The growth was driven by the successful execution of management's growth strategies, which are focused on increasing sales to existing customers and the addition of targeted new customers.
AXGN: 3.85 (+0.17)
AxoGen, Inc. to Report Third Quarter Financial Results on November 13, 2014
GlobeNewswire - Thu Nov 06, 6:09AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the third quarter ended September 30, 2014 on Thursday, November 13, 2014 after the market closes.
AXGN: 3.85 (+0.17)
AxoGen (AXGN) Shows Strength: Stock Up 15.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 8:39AM CDT
AxoGen, Inc. (AXGN) was a big mover last session, as its shares rose over 15% on the day.
MNK: 97.84 (-0.29), ACT: 254.20 (-1.68), AXGN: 3.85 (+0.17), MYL: 56.97 (+0.39)
AxoGen, Inc. Announces Presentation of Clinical Data for Avance(R) Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting
GlobeNewswire - Tue Sep 30, 6:05AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced the presentation of clinical data for Avance(R) Nerve Graft during the American Society for Surgery of the Hand (ASSH) 2014 Annual Meeting which took place last week in Boston.
AXGN: 3.85 (+0.17)